What's Going On With Opiate Screening Tests-Focused Intelligent Bio Solutions Stock On Monday?
What's Going On With Opiate Screening Tests-Focused Intelligent Bio Solutions Stock On Monday?
Monday, Intelligent Bio Solutions Inc. (NASDAQ:INBS) stock is trading higher with a session volume of 62.49 million compared to the average volume of 154k, as per data from Benzinga Pro.
Benzinga Pro的數據顯示，週一，智能生物解決方案公司（納斯達克股票代碼：INBS）股票交易量上漲，交易日交易量爲6249萬，而平均交易量爲15.4萬。
The company reported preliminary fiscal fourth-quarter 2024 revenue of $0.73 million, up 64% year-over-year compared to the consensus of $1.43 million.
該公司報告稱，2024財年第四季度初步收入爲73萬美元，同比增長64％，而市場預期的143萬美元。
The fiscal year 2024 sales increased 148% to $3.11 million compared to the consensus of $4.18 million.
2024財年的銷售額增長了148％，達到311萬美元，而市場普遍的銷售額爲418萬美元。
INBS expects a 20% increase in cartridge sales and a 26% increase in reader sales for 2024.
INBS預計，到2024年，墨盒的銷量將增長20％，閱讀器的銷量將增長26％。
The company attributes key drivers of revenue growth to market demand, increasing brand and product awareness, and expansion of its customer base.
該公司將收入增長的關鍵驅動因素歸因於市場需求、品牌和產品知名度的提高以及客戶群的擴大。
The company announced on Thursday its progress toward completing the clinical study plan required for its FDA 510(k) submission.
該公司週四宣佈了在完成提交FDA 510（k）所需的臨床研究計劃方面取得的進展。
Intelligent Bio Solutions is a medical technology company offering rapid, non-invasive testing solutions.
Intelligent Bio Solutions是一家提供快速、非侵入性測試解決方案的醫療技術公司。
In August 2024, Intelligent Bio Solutions announced its partnership with CenExel to perform the method comparison study as part of its clinical study plan.
2024年8月，智能生物解決方案宣佈與CeneXel合作，進行方法比較研究，這是其臨床研究計劃的一部分。
The study involves recruiting 135 healthy adult subjects and comparing the results of fingerprint sweat opiate screening tests.
該研究涉及招募135名健康的成年受試者，並比較指紋汗液阿片類藥物篩查測試的結果。
The company completed approximately one-third of the subject enrollment targets for its method comparison study, including screening, consenting, and fingerprint sweat specimen collection activities.
該公司完成了大約三分之一的方法比較研究受試者入組目標，包括篩查、同意和指紋汗液樣本收集活動。
Additionally, the company recently completed the in-clinic portion of a pharmacokinetic (PK) study on opiates in human fingerprint sweat and is currently analyzing the collected specimens and data from the study.
此外，該公司最近完成了一項針對人體指紋汗液中阿片類藥物的藥代動力學（PK）研究的臨床部分，目前正在分析從該研究中收集的標本和數據。
Harry Simeonidis, President and CEO at INBS, commented, "Our team and CRO partner are working together effectively to remain on track with our plan to complete the in-clinic portion of the method comparison study by the end of September. This progress aligns with our overarching goal of preparing a 510(k) submission for the FDA in the fourth calendar quarter of 2024."
INBS總裁兼首席執行官哈里·西蒙尼迪斯評論說：「我們的團隊和CRO合作伙伴正在有效合作，以按計劃在9月底之前完成方法比較研究的臨床內部分。這一進展符合我們的總體目標，即在2024年第四個日曆季度準備向美國食品藥品管理局提交510（k）份申請。」
The Intelligent Fingerprinting Drug Screening System, consisting of a DSR-Plus portable analysis unit and tamper-proof cartridges, is designed to offer drug detection using lateral flow assay technology and fluorescence-labeled antibodies to analyze sweat from fingerprints.
智能指紋藥物篩選系統由 DSR-Plus 便攜式分析裝置和防篡改墨盒組成，旨在使用側向流分析技術和熒光標記抗體進行藥物檢測，以分析指紋中的汗液。
Results are available within 10 minutes, with a 16-hour detection window for drug use.
10 分鐘內即可得出結果，毒品使用檢測窗口爲 16 小時。
In August, the company announced the installation of over 1,000 Intelligent Fingerprinting Drug Screening Readers with customers as of June 30, 2024.
8月，該公司宣佈，截至2024年6月30日，將向客戶安裝超過1,000台智能指紋藥物篩選閱讀器。
The company sold 407 readers in the fiscal year ending June 30, 2024, a 26% increase from the prior fiscal year.
在截至2024年6月30日的財年中，該公司售出了407名讀者，比上一財年增長了26％。
As of June 30, 2024, the total number of installed readers was 1,037, a 65% increase from 630 installed readers as of June 30, 2023.
截至2024年6月30日，安裝的閱讀器總數爲1,037個，較截至2023年6月30日的630個已安裝的閱讀器增加了65％。
Price Action: INBS stock is up 77.80% at $2.81 at the last check on Monday.
價格走勢：週一最後一次支票時，INBS股價上漲77.80％，至2.81美元。
譯文內容由第三人軟體翻譯。